当前位置: 首页 >> 检索结果
261. Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.
作者: Yann Gouëffic.;Giovanni Torsello.;Thomas Zeller.;Giovanni Esposito.;Frank Vermassen.;Klaus Armin Hausegger.;Gunnar Tepe.;Marcus Thieme.;Michael Gschwandtner.;Andrea Kahlberg.;Marc Schindewolf.;Marc Sapoval.;Juan Diaz-Cartelle.;Konstantinos Stavroulakis.; .
来源: Circulation. 2022年146卷21期1564-1576页
A clear patency benefit of a drug-eluting stent (DES) over bare metal stents (BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been definitively demonstrated. The EMINENT study (Trial Comparing Eluvia Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery) was designed to evaluate the patency of the Eluvia DES (Boston Scientific, Marlborough, MA), a polymer-coated paclitaxel-eluting stent, compared with BMSs for the treatment of femoropopliteal artery lesions.
262. Impact of Different Training Modalities on Molecular Alterations in Skeletal Muscle of Patients With Heart Failure With Preserved Ejection Fraction: A Substudy of the OptimEx Trial.
作者: Ephraim B Winzer.;Antje Augstein.;Antje Schauer.;Stephan Mueller.;Tina Fischer-Schaepmann.;Keita Goto.;Jennifer Hommel.;Emeline M van Craenenbroeck.;Ulrik Wisløff.;Burkert Pieske.;Martin Halle.;Axel Linke.;Volker Adams.
来源: Circ Heart Fail. 2022年15卷10期e009124页
Exercise intolerance is a cardinal feature of heart failure with preserved ejection fraction and so far exercise training (ET) is the most effective treatment. Since the improvement in exercise capacity is only weakly associated with changes in diastolic function other mechanisms, like changes in the skeletal muscle, contribute to improvement in peak oxygen consumption. The aim of the present study was to analyze molecular changes in skeletal muscle of patients with heart failure with preserved ejection fraction performing different ET modalities.
263. Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial.
作者: Roy O Mathew.;David J Maron.;Rebecca Anthopolos.;Jerome L Fleg.;Sean M O'Brien.;Frank W Rockhold.;Carlo Briguori.;Marek F Roik.;Tomasz Mazurek.;Marcin Demkow.;Robert Malecki.;Zhiming Ye.;Upendra Kaul.;Marius Miglinas.;Gregg W Stone.;Ron Wald.;David M Charytan.;Mandeep S Sidhu.;Judith S Hochman.;Sripal Bangalore.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷10期e008995页
Patients with chronic kidney disease (CKD) on dialysis (CKD G5D) have worse cardiovascular outcomes than patients with advanced nondialysis CKD (CKD G4-5: estimated glomerular filtration rate <30 mL/[min·1.73m2]). Our objective was to evaluate the relationship between achievement of cardiovascular guideline-directed medical therapy (GDMT) goals and clinical outcomes for CKD G5D versus CKD G4-5.
264. Preventive Effect of Berberine on Postoperative Atrial Fibrillation.
作者: Jian Zhang.;Yang Wang.;Hui Jiang.;Dengshun Tao.;Keyan Zhao.;Zongtao Yin.;Jinsong Han.;Fangran Xin.;Yan Jin.;Huishan Wang.
来源: Circ Arrhythm Electrophysiol. 2022年15卷10期e011160页
Postoperative atrial fibrillation (POAF) is one of the most common complications of cardiac surgery, but the underlying factors governing POAF are not well understood. The aim of this study was to investigate the efficacy of berberine administration on POAF.
265. Temperature Control After In-Hospital Cardiac Arrest: A Randomized Clinical Trial.
作者: Sebastian Wolfrum.;Kevin Roedl.;Alexia Hanebutte.;Rüdiger Pfeifer.;Volkhard Kurowski.;Reimer Riessen.;Anne Daubmann.;Stephan Braune.;Gerold Söffker.;Eric Bibiza-Freiwald.;Karl Wegscheider.;Heribert Schunkert.;Holger Thiele.;Stefan Kluge.; .
来源: Circulation. 2022年146卷18期1357-1366页
This study was conducted to determine the effect of hypothermic temperature control after in-hospital cardiac arrest (IHCA) on mortality and functional outcome as compared with normothermia.
266. A Mechanistic Clinical Trial Using (R)- Versus (S)-Propafenone to Test RyR2 (Ryanodine Receptor) Inhibition for the Prevention of Atrial Fibrillation Induction.
作者: M Benjamin Shoemaker.;Zachary T Yoneda.;Diane M Crawford.;Wendell S Akers.;Travis Richardson.;Jay A Montgomery.;Sharon Phillips.;Yu Shyr.;Pablo Saavedra.;Juan C Estrada.;Arvindh Kanagasundram.;Sharon T Shen.;Gregory F Michaud.;George Crossley.;Christopher R Ellis.;Bjorn C Knollmann.
来源: Circ Arrhythm Electrophysiol. 2022年15卷10期e010713页
Experimental data suggest ryanodine receptor-mediated intracellular calcium leak is a mechanism for atrial fibrillation (AF), but evidence in humans is still needed. Propafenone is composed of two enantiomers that are equally potent sodium-channel blockers; however, (R)-propafenone is an ryanodine receptor inhibitor whereas (S)-propafenone is not. This study tested the hypothesis that ryanodine receptor inhibition with (R)-propafenone prevents induction of AF compared to (S)-propafenone or placebo in patients referred for AF ablation.
267. Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.
作者: Ali Javaheri.;Ahmed Diab.;Lei Zhao.;Chenao Qian.;Jordana B Cohen.;Payman Zamani.;Anupam Kumar.;Zhaoqing Wang.;Christina Ebert.;Joseph Maranville.;Erika Kvikstad.;Michael Basso.;Vanessa van Empel.;A Mark Richards.;Robert N Doughty.;Ernst Rietzschel.;Karl Kammerhoff.;Joseph Gogain.;Peter Schafer.;Dietmar A Seiffert.;David A Gordon.;Francisco Ramirez-Valle.;Douglas L Mann.;Thomas P Cappola.;Julio A Chirinos.
来源: Circ Heart Fail. 2022年15卷9期e009693页
The TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) suggested clinical benefits of spironolactone treatment among patients with heart failure with preserved ejection fraction enrolled in the Americas. However, a comprehensive assessment of biologic pathways impacted by spironolactone therapy in heart failure with preserved ejection fraction has not been performed.
268. Prognostic Value of Measuring Fractional Flow Reserve After Percutaneous Coronary Intervention in Patients With Complex Coronary Artery Disease: Insights From the FAME 3 Trial.
作者: Zsolt Piroth.;Hisao Otsuki.;Frederik M Zimmermann.;Tamás Ferenci.;Danielle C J Keulards.;Alan C Yeung.;Nico H J Pijls.;Bernard De Bruyne.;William F Fearon.
来源: Circ Cardiovasc Interv. 2022年15卷11期884-891页
We evaluate the prognostic value of measuring fractional flow reserve (FFR) after percutaneous coronary intervention (post-PCI FFR) and intravascular imaging in patients undergoing PCI for 3-vessel coronary artery disease in the FAME 3 trial (Fractional Flow Reserve versus Angiography for Multivessel Evaluation).
269. Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Artery Disease: Extended Follow-Up Outcomes of Multicenter Randomized Controlled BEST Trial.
作者: Jung-Min Ahn.;Do-Yoon Kang.;Sung-Cheol Yun.;Seung Ho Hur.;Hun-Jun Park.;Damras Tresukosol.;Woong Chol Kang.;Hyuck Moon Kwon.;Seung-Woon Rha.;Do-Sun Lim.;Myung-Ho Jeong.;Bong-Ki Lee.;He Huang.;Young Hyo Lim.;Jang Ho Bae.;Byung Ok Kim.;Tiong Kiam Ong.;Sung Gyun Ahn.;Cheol-Hyun Chung.;Duk-Woo Park.;Seung-Jung Park.; .
来源: Circulation. 2022年146卷21期1581-1590页
Long-term comparative outcomes after percutaneous coronary intervention (PCI) with everolimus-eluting stents and coronary artery bypass grafting (CABG) are limited in patients with multivessel coronary artery disease.
270. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
作者: Javed Butler.;Gerasimos Filippatos.;Tariq Jamal Siddiqi.;João Pedro Ferreira.;Martina Brueckmann.;Edimar Bocchi.;Michael Böhm.;Vijay K Chopra.;Nadia Giannetti.;Tomoko Iwata.;James L Januzzi.;Sanjay Kaul.;Ileana L Piña.;Piotr Ponikowski.;Ursula Rauch-Kröhnert.;Sanjiv J Shah.;Michele Senni.;Mikhail Sumin.;Subodh Verma.;Jian Zhang.;Stuart J Pocock.;Faiez Zannad.;Milton Packer.;Stefan D Anker.
来源: Circulation. 2022年146卷14期1046-1055页
Women and men with heart failure (HF) and preserved ejection fraction may differ in their clinical characteristics and their response to therapy. The aim of this study was to evaluate the influence of sex on the effects of empagliflozin in patients with HF and preserved ejection fraction enrolled in the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction).
271. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
作者: Amil M Shah.;Brian Claggett.;Narayana Prasad.;Guichu Li.;Mayra Volquez.;Karola Jering.;Maja Cikes.;Attila Kovacs.;Wilfried Mullens.;Jose C Nicolau.;Lars Køber.;Peter van der Meer.;Pardeep S Jhund.;Ghionul Ibram.;Martin Lefkowitz.;Yinong Zhou.;Scott D Solomon.;Marc A Pfeffer.
来源: Circulation. 2022年146卷14期1067-1081页
Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV) enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits with combined angiotensin receptor neprilysin inhibition, but human data are conflicting. The PARADISE-MI Echo Study (Prospective ARNI Versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction) tested the effect of sacubitril/valsartan compared with ramipril on LV function and adverse remodeling after high risk-AMI.
272. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study.
作者: Jonas Oldgren.;Signild Åsberg.;Ziad Hijazi.;Per Wester.;Maria Bertilsson.;Bo Norrving.; .
来源: Circulation. 2022年146卷14期1056-1066页
There are no evidence-based recommendations on the optimal time point to initiate non-vitamin K antagonist oral anticoagulants (NOACs) after acute ischemic stroke in patients with atrial fibrillation. We aimed to investigate the efficacy and safety of early versus delayed initiation of NOAC in these patients.
273. Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B.
作者: Marc P Bonaca.;David A Morrow.;Brian A Bergmark.;David D Berg.;Joao A C Lima.;Udo Hoffmann.;Yoko Kato.;Michael T Lu.;Julia Kuder.;Sabina A Murphy.;Jindrich Spinar.;Ton Oude Ophuis.;Róbert G Kiss.;Jose Lopez-Sendon.;Oleg Averkov.;Stephen B Wheatcroft.;Jacek Kubica.;Jose Carlos Nicolau.;Remo H M Furtado.;Liron Abuhatzira.;Boaz Hirshberg.;Sami A Omar.;Andrea L Vavere.;Yi-Ting Chang.;Richard T George.;Marc S Sabatine.
来源: Circulation. 2022年146卷12期907-916页
High-density lipoprotein plays a key role in reverse cholesterol transport. In addition, high-density lipoprotein particles may be cardioprotective and reduce infarct size in the setting of myocardial injury. Lecithin-cholesterol acyltransferase is a rate-limiting enzyme in reverse cholesterol transport. MEDI6012 is a recombinant human lecithin-cholesterol acyltransferase that increases high-density lipoprotein cholesterol. Administration of lecithin-cholesterol acyltransferase has the potential to reduce infarct size and regress coronary plaque in acute ST-segment-elevation myocardial infarction.
274. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT.
作者: Erin A Bohula.;David D Berg.;Mathew S Lopes.;Jean M Connors.;Ijlal Babar.;Christopher F Barnett.;Sunit-Preet Chaudhry.;Amit Chopra.;Wilson Ginete.;Michael H Ieong.;Jason N Katz.;Edy Y Kim.;Julia F Kuder.;Emilio Mazza.;Dalton McLean.;Jarrod M Mosier.;Ari Moskowitz.;Sabina A Murphy.;Michelle L O'Donoghue.;Jeong-Gun Park.;Rajnish Prasad.;Christian T Ruff.;Mohamad N Shahrour.;Shashank S Sinha.;Stephen D Wiviott.;Sean Van Diepen.;Mark Zainea.;Vivian Baird-Zars.;Marc S Sabatine.;David A Morrow.; .
来源: Circulation. 2022年146卷18期1344-1356页
The efficacy and safety of prophylactic full-dose anticoagulation and antiplatelet therapy in critically ill COVID-19 patients remain uncertain.
275. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
作者: Michelle L O'Donoghue.;Robert P Giugliano.;Stephen D Wiviott.;Dan Atar.;Anthony Keech.;Julia F Kuder.;KyungAh Im.;Sabina A Murphy.;Jose H Flores-Arredondo.;J Antonio G López.;Mary Elliott-Davey.;Bei Wang.;Maria Laura Monsalvo.;Siddique Abbasi.;Marc S Sabatine.
来源: Circulation. 2022年146卷15期1109-1119页
In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and risk of cardiovascular events and was safe and well tolerated over a median of 2.2 years of follow-up. However, large-scale, long-term data are lacking.
276. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
作者: Sunil V Rao.;Bodo Kirsch.;Deepak L Bhatt.;Andrzej Budaj.;Rosa Coppolecchia.;John Eikelboom.;Stefan K James.;W Schuyler Jones.;Bela Merkely.;Lars Keller.;Renicus S Hermanides.;Gianluca Campo.;José Luis Ferreiro.;Taro Shibasaki.;Hardi Mundl.;John H Alexander.; .
来源: Circulation. 2022年146卷16期1196-1206页
Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI).
277. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.
作者: Alexander Peikert.;Felipe A Martinez.;Muthiah Vaduganathan.;Brian L Claggett.;Ian J Kulac.;Akshay S Desai.;Pardeep S Jhund.;Rudolf A de Boer.;David DeMets.;Adrian F Hernandez.;Silvio E Inzucchi.;Mikhail N Kosiborod.;Carolyn S P Lam.;Sanjiv J Shah.;Tsvetana Katova.;Béla Merkely.;Orly Vardeny.;Ulrica Wilderäng.;Daniel Lindholm.;Magnus Petersson.;Anna Maria Langkilde.;John J V McMurray.;Scott D Solomon.
来源: Circ Heart Fail. 2022年15卷10期e010080页
The prevalence of heart failure with mildly reduced or preserved ejection fraction markedly increases with age, with older individuals disproportionately facing excess risk for mortality and hospitalization.
278. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.
作者: Jawad H Butt.;Pardeep S Jhund.;Jan Belohlávek.;Rudolf A de Boer.;Chern-En Chiang.;Akshai S Desai.;Jarosław Drożdż.;Adrian F Hernandez.;Silvio E Inzucchi.;Tzvetana Katova.;Masafumi Kitakaze.;Mikhail N Kosiborod.;Carolyn S P Lam.;Anna Maria Langkilde.;Daniel Lindholm.;Erasmus Bachus.;Felipe Martinez.;Béla Merkely.;Magnus Petersson.;Jose F Kerr Saraiva.;Sanjiv J Shah.;Muthiah Vaduganathan.;Orly Vardeny.;Ulrica Wilderäng.;Brian L Claggett.;Scott D Solomon.;John J V McMurray.
来源: Circulation. 2022年146卷16期1210-1224页
Frailty is increasing in prevalence. Because patients with frailty are often perceived to have a less favorable risk/benefit profile, they may be less likely to receive new pharmacologic treatments. We investigated the efficacy and tolerability of dapagliflozin according to frailty status in patients with heart failure with mildly reduced or preserved ejection fraction randomized in DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure).
279. Sequential Interventions for Major Depression and Heart Failure Self-Care: A Randomized Clinical Trial.
作者: Kenneth E Freedland.;Judith A Skala.;Robert M Carney.;Brian C Steinmeyer.;Eugene H Rubin.;Michael W Rich.
来源: Circ Heart Fail. 2022年15卷8期e009422页
Major depression and inadequate self-care are common in patients with heart failure (HF). Little is known about how to intervene when both problems are present. This study examined the efficacy of a sequential approach to treating these problems.
280. Cardiovascular and Renal Implications of Myocardial Infarction in the ISCHEMIA-CKD Trial.
作者: Bernard R Chaitman.;Derek D Cyr.;Karen P Alexander.;Radosław Pracoń.;Kevin R Bainey.;Anoop Mathew.;Anjali Acharya.;Dennis F Kunichoff.;Jerome L Fleg.;Renato D Lopes.;Mandeep S Sidhu.;Rebecca Anthopolos.;Frank W Rockhold.;Gregg W Stone.;David J Maron.;Judith S Hochman.;Sripal Bangalore.
来源: Circ Cardiovasc Interv. 2022年15卷8期e012103页
ISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease) reported an initial invasive treatment strategy did not reduce the risk of death or nonfatal myocardial infarction (MI) compared with a conservative treatment strategy in patients with advanced chronic kidney disease, stable coronary disease, and moderate or severe myocardial ischemia. The cumulative frequency of different MI type after randomization and subsequent prognosis have not been reported.
|